Butyrate, neuroepigenetics and the gut microbiome: Can a high fiber diet improve brain health?

Neuroscience Letters

Volumn 625, Issue , 2016, Pages 56-63

  Bourassa, Megan W ^a,b   Alim, Ishraq ^a,b   Bultman, Scott J ^c   Ratan, Rajiv R ^a,b  

^a BURKE MEDICAL RESEARCH INSTITUTE   (United States)

^b FEIL FAMILY BRAIN AND MIND RESEARCH INSTITUTE   (United States)

^c UNIVERSITY OF NORTH CAROLINA SCHOOL OF MEDICINE   (United States)

Author keywords

Butyrate; Gut microbiome; Gut brain axis; High fiber diet; Neuroepigenetics

Indexed keywords

3 HYDROXYBUTYRIC ACID; BUTYRIC ACID; G PROTEIN COUPLED RECEPTOR; HISTONE DEACETYLASE INHIBITOR; BUTYRIC ACID DERIVATIVE;

BRAIN; BRAIN DISEASE; COGNITION; DIETARY FIBER; ENERGY METABOLISM; EPIGENETICS; FERMENTATION; GASTROENTEROLOGY; GENE EXPRESSION; HIGH FIBER DIET; HUMAN; INTESTINE FLORA; MENTAL DISEASE; MICROBIOME; MITOCHONDRIAL RESPIRATION; NERVE DEGENERATION; NERVE REGENERATION; NEUROLOGIC DISEASE; NEUROSCIENCE; NONHUMAN; PRIORITY JOURNAL; REVIEW; ANIMAL; GENETIC EPIGENESIS; METABOLISM; MITOCHONDRION; PHYSIOLOGY;

ANIMALS; BRAIN; BUTYRATES; COGNITION; DIETARY FIBER; EPIGENESIS, GENETIC; GASTROINTESTINAL MICROBIOME; HISTONE DEACETYLASE INHIBITORS; HUMANS; MITOCHONDRIA; RECEPTORS, G-PROTEIN-COUPLED;

EID: 84958279436     PISSN: 03043940     EISSN: 18727972     Source Type: Journal    
DOI: 10.1016/j.neulet.2016.02.009     Document Type: Review

References (102)

1. Frank D.N., St Amand A.L., Feldman R.A., Boedeker E.C., Harpaz N., Pace N.R. Molecular-phylogenetic characterization of microbial community imbalances in human inflammatory bowel diseases. Proc. Natl. Acad. Sci. U. S. A. 2007, 104:13780-13785.
2. Stilling R.M., Dinan T.G., Cryan J.F. Microbial genes, brain & behaviour - epigenetic regulation of the gut-brain axis. Genes Brain Behav. 2014, 13:69-86.
3. Sudo N., Chida Y., Aiba Y., Sonoda J., Oyama N., Yu X.-N., et al. Postnatal microbial colonization programs the hypothalamic-pituitary-adrenal system for stress response in mice. J. Physiol. 2004, 558:263-275.
4. Layden B.T., Angueira A.R., Brodsky M., Durai V., Lowe W.L. Short chain fatty acids and their receptors: new metabolic targets. Transl. Res. 2013, 161:131-140.
5. Selkrig J., Wong P., Zhang X., Pettersson S. Metabolic tinkering by the gut microbiome: implications for brain development and function. Gut Microbes 2014, 5:369-380.
6. Gottschalk G. Bacterial Metabolism 1979, 1. Springer-Verlag, New York.
7. Pryde S.E., Duncan S.H., Hold G.L., Stewart C.S., Flint H.J. The microbiology of butyrate formation in the human colon. FEMS Microbiol. Lett. 2002, 217:133-139.
8. Barcenilla A., Pryde S.E., Martin J.C., Duncan S.H., Stewart C.S., Henderson C., et al. Phylogenetic relationships of butyrate-producing bacteria from the human gut. Appl. Environ. Microbiol. 2000, 66:1654-1661.
9. Cummings J.H., Rombeau J.L., Sakata T. Physiological and Clinical Aspects of Short-Chain Fatty Acids 2016, Cambridge University Press, 2004.
10. Topping D.L., Clifton P.M. Short-Chain fatty acids and human colonic function: roles of resistant starch and nonstarch polysaccharides. Physiol. Rev. 2001, 81:1031-1064.
11. Le Blay G., Michel C., Blottiere H.M., Cherbut C. Prolonged intake of fructo-oligosaccharides induces a short-term elevation of lactic acid-producing bacteria and a persistent increase in cecal butyrate in rats. J. Nutr. 1999, 129:2231-2235.
12. Perrin P. Only fibres promoting a stable butyrate producing colonic ecosystem decrease the rate of aberrant crypt foci in rats. Gut 2001, 48:53-61.
13. Pouteau E., Nguyen P., Ballèvre O., Krempf M. Production rates and metabolism of short-chain fatty acids in the colon and whole body using stable isotopes. Proc. Nutr. Soc. 2003, 62:87-93.
14. Wolever T.M.S., Josse R.G., Leiter L.A., Chiasson J.-L. Time of day and glucose tolerance status affect serum short-chain fatty concentrations in humans. Metabolism 1997, 46:805-811.
15. Newmark H.L., Lupton J.R., Young C.W. Butyrate as a differentiating agent: pharmacokinetics, analogues and current status. Cancer Lett. 1994, 78:1-5.
16. Parodi P.W. Conjugated linoleic acid and other anticarcinogenic agents of bovine milk fat. J. Dairy Sci. 1999, 82:1339-1349.
17. Leonel A.J., Alvarez-Leite J.I. Butyrate: implications for intestinal function. Curr. Opin. Clin. Nutr. Metab. Care 2012, 15:474-479.
18. Miyoshi M., Sakaki H., Usami M., Iizuka N., Shuno K., Aoyama M., et al. Oral administration of tributyrin increases concentration of butyrate in the portal vein and prevents lipopolysaccharide-induced liver injury in rats. Clin. Nutr. 2011, 30:252-258.
19. Sleiman S.F., Basso M., Mahishi L., Kozikowski A.P., Donohoe M.E., Langley B., et al. Putting the HAT back on survival signalling: the promises and challenges of HDAC inhibition in the treatment of neurological conditions. Expert Opin. Invest. Drugs. 2009, 18:573-584.
20. Sealy L. The effect of sodium butyrate on histone modification. Cell 1978, 14:115-121.
21. Candido E. Sodium butyrate inhibits histone deacetylation in cultured cells. Cell 1978, 14:105-113.
22. Ryu H., Lee J., Olofsson B.A., Mwidau A., Dedeoglu A., Escudero M., et al. Histone deacetylase inhibitors prevent oxidative neuronal death independent of expanded polyglutamine repeats via an Sp1-dependent pathway. Proc. Natl. Acad. Sci. U. S. A. 2003, 100:4281-4286.
23. Ferrante R.J., Kubilus J.K., Lee J., Ryu H., Beesen A., Zucker B., et al. Histone deacetylase inhibition by sodium butyrate chemotherapy ameliorates the neurodegenerative phenotype in huntington's disease mice. J. Neurosci. 2003, 23:9418-9427.
24. Langley B., D'Annibale M.A., Suh K., Ayoub I., Tolhurst A., Bastan B., et al. Pulse inhibition of histone deacetylases induces complete resistance to oxidative death in cortical neurons without toxicity and reveals a role for cytoplasmic p21(waf1/cip1) in cell cycle-independent neuroprotection. J. Neurosci. 2008, 28:163-176.
25. Camelo S., Iglesias A.H., Hwang D., Due B., Ryu H., Smith K., et al. Transcriptional therapy with the histone deacetylase inhibitor trichostatin A ameliorates experimental autoimmune encephalomyelitis. J. Neuroimmunol. 2005, 164:10-21.
26. Gardian G., Browne S.E., Choi D.-K., Klivenyi P., Gregorio J., Kubilus J.K., et al. Neuroprotective effects of phenylbutyrate in the N171-82Q transgenic mouse model of Huntington's disease. J. Biol. Chem. 2005, 280:556-563.
27. Sharma S., Taliyan R., Singh S. Beneficial effects of sodium butyrate in 6-OHDA induced neurotoxicity and behavioral abnormalities: modulation of histone deacetylase activity. Behav. Brain Res. 2015, 291:306-314.
28. Kidd S.K., Schneider J.S. Protection of dopaminergic cells from MPP+-mediated toxicity by histone deacetylase inhibition. Brain Res. 2010, 1354:172-178.
29. St Laurent R., O'Brien L.M., Ahmad S.T. Sodium butyrate improves locomotor impairment and early mortality in a rotenone-induced Drosophila model of Parkinson's disease. Neuroscience 2013, 246:382-390.
30. Drottar M., Liberman M.C., Ratan R.R., Roberson D.W. The histone deacetylase inhibitor sodium butyrate protects against cisplatin-induced hearing loss in guinea pigs. Laryngoscope 2006, 116:292-296.
31. Kim H.J., Chuang D.-M. HDAC inhibitors mitigate ischemia-induced oligodendrocyte damage: potential roles of oligodendrogenesis, VEGF, and anti-inflammation. Am. J. Transl. Res. 2014, 6:206-223.
32. Wang Z., Leng Y., Tsai L.-K., Leeds P., Chuang D.-M. Valproic acid attenuates blood-brain barrier disruption in a rat model of transient focal cerebral ischemia: the roles of HDAC and MMP-9 inhibition. J. Cereb. Blood Flow Metab. 2011, 31:52-57.
33. Kim H.J., Rowe M., Ren M., Hong J.-S., Chen P.-S., Chuang D.-M. Histone deacetylase inhibitors exhibit anti-inflammatory and neuroprotective effects in a rat permanent ischemic model of stroke: multiple mechanisms of action. J. Pharmacol. Exp. Ther. 2007, 321:892-901.
34. Sleiman S.F., Berlin J., Basso M., Karuppagounder S.S., Rohr J., Ratan R.R. Histone deacetylase inhibitors and mithramycin a impact a similar neuroprotective pathway at a crossroad between cancer and neurodegeneration. Pharmaceuticals (Basel) 2011, 4:1183-1195.
35. Govindarajan N., Agis-Balboa R.C., Walter J., Sananbenesi F., Fischer A. Sodium butyrate improves memory function in an Alzheimer's disease mouse model when administered at an advanced stage of disease progression. J. Alzheimers Dis. 2011, 26:187-197.
36. Kilgore M., Miller C.A., Fass D.M., Hennig K.M., Haggarty S.J., Sweatt J.D., et al. Inhibitors of class 1 histone deacetylases reverse contextual memory deficits in a mouse model of Alzheimer's disease. Neuropsychopharmacology 2010, 35:870-880.
37. Sharma B., Sharma P.M. Arsenic toxicity induced endothelial dysfunction and dementia: pharmacological interdiction by histone deacetylase and inducible nitric oxide synthase inhibitors. Toxicol. Appl. Pharmacol. 2013, 273:180-188.
38. da Silva P.F., Garcia V.A., da A., Dornelles S., da Silva V.K., Maurmann N., Portal B.C.D., et al. Memory impairment induced by brain iron overload is accompanied by reduced H3K9 acetylation and ameliorated by sodium butyrate. Neuroscience 2012, 200:42-49.
39. Dash P.K., Orsi S.A., Moore A.N. Histone deactylase inhibition combined with behavioral therapy enhances learning and memory following traumatic brain injury. Neuroscience 2009, 163:1-8.
40. Steckert A.V., Comim C.M., Igna D.M.D., Dominguini D., Mendonça B.P., Ornell F., et al. Effects of sodium butyrate on aversive memory in rats submitted to sepsis. Neurosci. Lett. 2015, 595:134-138.
41. Barichello T., Generoso J.S., Simões L.R., Faller C.J., Ceretta R.A., Petronilho F., et al. Sodium butyrate prevents memory impairment by Re-establishing BDNF and GDNF expression in experimental pneumococcal meningitis. Mol. Neurobiol. 2015, 52:734-740.
42. Suzuki-Mizushima Y., Gohda E., Okamura T., Kanasaki K., Yamamoto I. Enhancement of NGF- and cholera toxin-induced neurite outgrowth by butyrate in PC12 cells. Brain Res. 2002, 951:209-217.
43. Wu X., Chen P.S., Dallas S., Wilson B., Block M.L., Wang C.-C., et al. Histone deacetylase inhibitors up-regulate astrocyte GDNF and BDNF gene transcription and protect dopaminergic neurons. Int. J. Neuropsychopharmacol. 2008, 11:1123-1134.
44. Mahan A.L., Mou L., Shah N., Hu J.-H., Worley P.F., Ressler K.J. Epigenetic modulation of Homer1a transcription regulation in amygdala and hippocampus with pavlovian fear conditioning. J. Neurosci. 2012, 32:4651-4659.
45. Wei Y., Melas P.A., Wegener G., Mathé A.A., Lavebratt C. Antidepressant-like effect of sodium butyrate is associated with an increase in TET1 and in 5-hydroxymethylation levels in the Bdnf gene. Int. J. Neuropsychopharmacol. 2015, 18:1-10.
46. Varela R.B., Valvassori S.S., Lopes-Borges J., Mariot E., Dal-Pont G.C., Amboni R.T., et al. Sodium butyrate and mood stabilizers block ouabain-induced hyperlocomotion and increase BDNF, NGF and GDNF levels in brain of Wistar rats. J. Psychiatry Res. 2015, 61:114-121.
47. Valvassori S.S., Varela R.B., Arent C.O., Dal-Pont G.C., Bobsin T.S., Budni J., et al. Sodium butyrate functions as an antidepressant and improves cognition with enhanced neurotrophic expression in models of maternal deprivation and chronic mild stress. Curr. Neurovasc. Res. 2014, 11:359-366.
48. Intlekofer K.A., Berchtold N.C., Malvaez M., Carlos A.J., McQuown S.C., Cunningham M.J., et al. Exercise and sodium butyrate transform a subthreshold learning event into long-term memory via a brain-derived neurotrophic factor-dependent mechanism. Neuropsychopharmacology 2013, 38:2027-2034.
49. Kumar A., Choi K.-H., Renthal W., Tsankova N.M., Theobald D.E.H., Truong H.-T., et al. Chromatin remodeling is a key mechanism underlying cocaine-induced plasticity in striatum. Neuron 2005, 48:303-314.
50. Pascual M., Do Couto B.R., Alfonso-Loeches S., Aguilar M.A., Rodriguez-Arias M., Guerri C. Changes in histone acetylation in the prefrontal cortex of ethanol-exposed adolescent rats are associated with ethanol-induced place conditioning. Neuropharmacology 2012, 62:2309-2319.
51. Ji M., Dong L., Jia M., Liu W., Zhang M., Ju L., et al. Epigenetic enhancement of brain-derived neurotrophic factor signaling pathway improves cognitive impairments induced by isoflurane exposure in aged rats. Mol. Neurobiol. 2014, 50:937-944.
52. Zhong T., Qing Q.J., Yang Y., Zou W.Y., Ye Z., Yan J.Q., et al. Repression of contexual fear memory induced by isoflurane is accompanied by reduction in histone acetylation and rescued by sodium butyrate. Br. J. Anaesth. 2014, 113:634-643.
53. Choudhary C., Kumar C., Gnad F., Nielsen M.L., Rehman M., Walther T.C., et al. Lysine acetylation targets protein complexes and co-regulates major cellular functions. Science 2009, 325:834-840.
54. Gensert J.M., Baranova O.V., Weinstein D.E., Ratan R.R. C.D.81, a cell cycle regulator, is a novel target for histone deacetylase inhibition in glioma cells. Neurobiol. Dis. 2007, 26:671-680.
55. Roediger W.E. Role of anaerobic bacteria in the metabolic welfare of the colonic mucosa in man. Gut 1980, 21:793-798.
56. Donohoe D.R., Garge N., Zhang X., Sun W., O'Connell T.M., Bunger M.K., et al. The microbiome and butyrate regulate energy metabolism and autophagy in the mammalian colon. Cell Metab. 2011, 13:517-526.
57. Donohoe D.R., Collins L.B., Wali A., Bigler R., Sun W., Bultman S.J. The Warburg effect dictates the mechanism of butyrate-mediated histone acetylation and cell proliferation. Mol. Cell. 2012, 48:612-626.
58. Friedland R.P., Budinger T.F., Ganz E., Yano Y., Mathis C.A., Koss B., et al. Regional cerebral metabolic alterations in dementia of the Alzheimer type: positron emission tomography with [18F]fluorodeoxyglucose. J. Comput. Assisted Tomogr. 1983, 7:590-598.
59. Mosconi L., Pupi A., De Leon M.J. Brain glucose hypometabolism and oxidative stress in preclinical Alzheimer's disease. Ann. N. Y. Acad. Sci. 2008, 1147:180-195.
60. Henderson S., Vogel J., Barr L. Study of the ketogenic agent AC-1202 in mild to moderate Alzheimer's disease: a randomized double-blind, placebo-controlled, multicenter trial. Nutr. Metab. 2009, 6:1-25.
61. Zhao S., Xu W., Jiang W., Yu W., Lin Y., Zhang T., et al. Regulation of cellular metabolism by protein lysine acetylation. Science 2010, 327:1000-1004.
62. Valvassori S.S., Calixto K.V., Budni J., Resende W.R., Varela R.B., de Freitas K.V., et al. Sodium butyrate reverses the inhibition of Krebs cycle enzymes induced by amphetamine in the rat brain. J. Neural Transm. 2013, 120:1737-1742.
63. Moretti M., Valvassori S.S., Varela R.B., Ferreira C.L., Rochi N., Benedet J., et al. Behavioral and neurochemical effects of sodium butyrate in an animal model of mania. Behav. Pharmacol. 2011, 22:766-772.
64. Lopes-Borges J., Valvassori S.S., Varela R.B., Tonin P.T., Vieira J.S., Gonçalves C.L., et al. Histone deacetylase inhibitors reverse manic-like behaviors and protect the rat brain from energetic metabolic alterations induced by ouabain. Pharmacol. Biochem. Behav. 2015, 128:89-95.
65. Vassart G., Costagliola S. G protein-coupled receptors: mutations and endocrine diseases. Nat. Rev. Endocrinol. 2011, 7:362-372.
66. Brown A.J., Goldsworthy S.M., Barnes A.A., Eilert M.M., Tcheang L., Daniels D., et al. The Orphan G protein-coupled receptors GPR41 and GPR43 are activated by propionate and other short chain carboxylic acids. J. Biol. Chem. 2003, 278:11312-11319.
67. Kimura I., Inoue D., Maeda T., Hara T., Ichimura A., Miyauchi S., et al. Short-chain fatty acids and ketones directly regulate sympathetic nervous system via G protein-coupled receptor 41 (GPR41). Proc. Natl. Acad. Sci. U. S. A. 2011, 108:8030-8035.
68. De Vadder F., Kovatcheva-Datchary P., Goncalves D., Vinera J., Zitoun C., Duchampt A., et al. Microbiota-generated metabolites promote metabolic benefits via gut-brain neural circuits. Cell 2014, 156:84-96.
69. Thangaraju M., Cresci G.A., Liu K., Ananth S., Gnanaprakasam J.P., Browning D.D., et al. GPR109A is a G-protein-coupled receptor for the bacterial fermentation product butyrate and functions as a tumor suppressor in colon. Cancer Res. 2009, 69:2826-2832.
70. Zimmerman M.A., Singh N., Martin P.M., Thangaraju M., Ganapathy V., Waller J.L., et al. Butyrate suppresses colonic inflammation through HDAC1-dependent Fas upregulation and Fas-mediated apoptosis of T cells. Am. J. Physiol. Gastrointest. Liver Physiol. 2012, 302:G1405-G1415.
71. Wakade C., Chong R., Bradley E., Thomas B., Morgan J. Upregulation of GPR109A in parkinson's disease. PLoS One 2014, 9:e109818.
72. Fu S.-P., Wang J.-F., Xue W.-J., Liu H.-M., Liu B., Zeng Y.-L., et al. Anti-inflammatory effects of BHBA in both in vivo and in vitro Parkinson's disease models are mediated by GPR109A-dependent mechanisms. J. Neuroinflammation 2015, 12:1-14.
73. Won Y.-J., Lu V.B., Puhl H.L., Ikeda S.R. β-Hydroxybutyrate modulates N-type calcium channels in rat sympathetic neurons by acting as an agonist for the G-protein-coupled receptor FFA3. J. Neurosci. 2013, 33:19314-19325.
74. Tarini J., Wolever T.M.S. The fermentable fibre inulin increases postprandial serum short-chain fatty acids and reduces free-fatty acids and ghrelin in healthy subjects. Appl. Physiol. Nutr. Metab. 2010, 35:9-16.
75. Wolever T.M.S., Chiasson J.-L. Acarbose raises serum butyrate in human subjects withimpaired glucose tolerance. Br. J. Nutr. 2000, 84:57-61.
76. Priebe M.G., Wang H., Weening D., Schepers M., Preston T., Vonk R.J. Factors related to colonic fermentation of nondigestible carbohydrates of a previous evening meal increase tissue glucose uptake and moderate glucose-associated inflammation. Am. J. Clin. Nutr. 2010, 91:90-97.
77. Robertson M.D., Bickerton A.S., Dennis A.L., Vidal H., Frayn K.N. Insulin-sensitizing effects of dietary resistant starch and effects on skeletal muscle and adipose tissue metabolism. Am. J. Clin. Nutr. 2005, 82:559-567.
78. Braniste V., Al-Asmakh M., Kowal C., Anuar F., Abbaspour A., Tóth M., et al. The gut microbiota influences blood-brain barrier permeability in mice. Sci. Transl. Med. 2014, 6:263ra158.
79. Sherry C.L., Kim S.S., Dilger R.N., Bauer L.L., Moon M.L., Tapping R.I., et al. Sickness behavior induced by endotoxin can be mitigated by the dietary soluble fiber pectin, through up-regulation of IL-4 and Th2 polarization. Brain. Behav. Immun. 2010, 24:631-640.
80. Khan N.A., Raine L.B., Drollette E.S., Scudder M.R., Kramer A.F., Hillman C.H. Dietary fiber is positively associated with cognitive control among prepubertal children. J. Nutr. 2015, 145:143-149.
81. Messaoudi M., Lalonde R., Violle N., Javelot H., Desor D., Nejdi A., et al. Assessment of psychotropic-like properties of a probiotic formulation (Lactobacillus helveticus R0052 and Bifidobacterium longum R0175) in rats and human subjects. Br. J. Nutr. 2010, 105:755-764.
82. Rao A.V., Bested A.C., Beaulne T.M., Katzman M.A., Iorio C., Berardi J.M., et al. A randomized double-blind, placebo-controlled pilot study of a probiotic in emotional symptoms of chronic fatigue syndrome. Gut Pathog. 2009, 1:1-6.
83. Tillisch K., Labus J., Kilpatrick L., Jiang Z., Stains J., Ebrat B., et al. Consumption of fermented milk product with probiotic modulates brain activity. Gastroenterology 2013, 144:1394-1401.
84. Adams J.B., Johansen L.J., Powell L.D., Quig D., Rubin R.A. Gastrointestinal flora and gastrointestinal status in children with autism-comparisons to typical children and correlation with autism severity. BMC Gastroenterol. 2011, 11:1-13.
85. Kang D.-W., Park J.G., Ilhan Z.E., Wallstrom G., Labaer J., Adams J.B., et al. Reduced incidence of Prevotella and other fermenters in intestinal microflora of autistic children. PLoS One 2013, 8:e68322.
86. Finegold S.M., Dowd S.E., Gontcharova V., Liu C., Henley K.E., Wolcott R.D., et al. Pyrosequencing study of fecal microflora of autistic and control children. Anaerobe 2010, 16:444-453.
87. Williams B.L., Hornig M., Parekh T., Lipkin W.I. Application of novel PCR-based methods for detection, quantitation, and phylogenetic characterization of Sutterella species in intestinal biopsy samples from children with autism and gastrointestinal disturbances. MBio 2012, 3:e00261-11.
88. Sandler R.H., Finegold S.M., Bolte E.R., Buchanan C.P., Maxwell A.P., Vaisanen M.-L., et al. Short-Term benefit from oral vancomycin treatment of regressive-Onset autism. J. Child Neurol. 2000, 15:429-435.
89. Wang L., Christophersen C.T., Sorich M.J., Gerber J.P., Angley M.T., Conlon M.A. Elevated fecal short chain fatty acid and ammonia concentrations in children with autism spectrum disorder. Dig. Dis. Sci. 2012, 57:2096-2102.
90. MacFabe D.F., Cain D.P., Rodriguez-Capote K., Franklin A.E., Hoffman J.E., Boon F., et al. Neurobiological effects of intraventricular propionic acid in rats: possible role of short chain fatty acids on the pathogenesis and characteristics of autism spectrum disorders. Behav. Brain Res. 2007, 176:149-169.
91. MacFabe D.F., Cain N.E., Boon F., Ossenkopp K.-P., Cain D.P. Effects of the enteric bacterial metabolic product propionic acid on object-directed behavior, social behavior, cognition, and neuroinflammation in adolescent rats: relevance to autism spectrum disorder. Behav. Brain Res. 2011, 217:47-54.
92. Thomas R.H., Foley K.A., Mepham J.R., Tichenoff L.J., Possmayer F., MacFabe D.F. Altered brain phospholipid and acylcarnitine profiles in propionic acid infused rodents: further development of a potential model of autism spectrum disorders. J. Neurochem. 2010, 113:515-529.
93. El-Ansary A.K., Ben Bacha A., Kotb M. Etiology of autistic features: the persisting neurotoxic effects of propionic acid. J. Neuroinflammation 2012, 9:1-14.
94. Brusque A., Mello C., Buchanan D., Terracciano S., Rocha M., Vargas C., et al. Effect of chemically induced propionic acidemia on neurobehavioral development of rats. Pharmacol. Biochem. Behav. 1999, 64:529-534.
95. MacFabe D.F., Rodriguez- K., Hoffman J.E., Franklin A.E., Mohammad-A Y., Taylor A.R., et al. A novel rodent model of autism: intraventricular infusions of propionic acid increase locomotor activity and induce neuroinflammation and oxidative stress in discrete regions of adult rat brain. Am. J. Biochem. Biotechnol 2008, 4:146-166.
96. Shultz S.R., MacFabe D.F., Martin S., Jackson J., Taylor R., Boon F., et al. Intracerebroventricular injections of the enteric bacterial metabolic product propionic acid impair cognition and sensorimotor ability in the long-Evans rat: further development of a rodent model of autism. Behav. Brain Res. 2009, 200:33-41.
97. Schneider T., Przewłocki R. Behavioral alterations in rats prenatally exposed to valproic acid: animal model of autism. Neuropsychopharmacology 2005, 30:80-89.
98. Ingram J.L., Peckham S.M., Tisdale B., Rodier P.M. Prenatal exposure of rats to valproic acid reproduces the cerebellar anomalies associated with autism. Neurotoxicol. Teratol. 2000, 22:319-324.
99. Christensen J., Grønborg T.K., Sørensen M.J., Schendel D., Parner E.T., Pedersen L.H., et al. Prenatal valproate exposure and risk of autism spectrum disorders and childhood autism. JAMA 2013, 309:1696-1703.
100. Cohen O.S., Varlinskaya E.I., Wilson C.A., Glatt S.J., Mooney S.M. Acute prenatal exposure to a moderate Dose of valproic acid increases social behavior and alters gene expression in rats. Int. J. Dev. Neurosci. 2013, 31:740-750.
101. Davidson M.P., Sofos J.N., Branen A.L. Antimicrobials in Food 2005, CRC Press. Third ed.
102. Smith J.G., Yokoyama W.H., German J.B. Butyric acid from the diet: actions at the level of gene expression. Crit. Rev. Food Sci. Nutr. 1998, 38:259-297.